Atrial high rate episodes in patients with dual-chamber cardiac implantable electronic devices: Unmasking silent atrial fibrillation

PACE - Pacing and Clinical Electrophysiology

Volumn 37, Issue 8, 2014, Pages 1080-1086

  Benezet Mazuecos, Juan ^a   Rubio, José Manuel ^a   Farré, Jerónimo ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

atrial fibrillation; atrial high rate episodes; cardiac implantable electronic devices; stroke

Indexed keywords

ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; ELECTROCARDIOGRAPHY; HEART ATRIUM; HUMAN; PATHOPHYSIOLOGY;

ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; ELECTROCARDIOGRAPHY; HEART ATRIA; HUMANS;

EID: 84905984853     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12428     Document Type: Review

References (38)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM,. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1982; 306: 1018-1022.
2. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
3. Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE,. The natural history of atrial fibrillation: Incidence, risk factors and prognosis in the Manitoba follow-up study. Am J Med 1995; 98: 476-484.
4. Savelieva I, Camm AJ,. Clinical relevance of silent atrial fibrillation: Prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4: 369-382.
5. Lin H-J, Wolf PA, Benjamin EJ, Belanger AJ, D'Agostino RB,. Newly diagnosed atrial fibrillation and acute stroke: The Framingham Study. Stroke 1995; 26: 1527-1530.
6. Feinberg WN, Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearce LA,. Asymptomatic cerebral infarction in patients with atrial fibrillation. Circulation 1988; 19: 955-957.
7. Ott A, Breteler MM, De Bruyne MC, Van Harskamp F, Grobbee DE, Hofman A,. Atrial fibrillation and dementia in a population-based study: The Rotterdam Study. Stroke 1997; 28: 316-321.
8. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL,. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy: Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35: 183-187.
9. McNamara RL, Brass LM, Drozda JP Jr., Go AS, Halperin JL, Kerr CR, Lévy S, et al. American College of Cardiology/American Heart Association task force on clinical data standards (Writing Committee to Develop Data Standards on Atrial Fibrillation); American College of Cardiology; American Heart Association. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on clinical data standards. Circulation 2004; 109: 3223-3243.
10. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, Connolly SJ,. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: An ACTIVE W Substudy. J Am Coll Cardiol 2007; 50: 2156-2161.
11. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz J, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: Results from the ARISTOTLE trial. Eur Heart J 2013; 34: 2464-2471.
12. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
13. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
14. Kerr C, Boone J, Connolly S, Greene M, Klein G, Shledon R, Talajic M,. Follow-up of atrial fibrillation: The initial experience of the Canadian registry of atrial fibrillation. Eur Heart J 1996; 17: 48-51.
15. Brand FN, Abbott RD, Kannel WB, Wolf PA,. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA 1985; 254: 3449-3453.
16. Nowak B,. Pacemaker stored electrograms: Teaching us what is really going on in our patients. Pacing Clin Electrophysiol 2002; 25: 838-849.
17. Seidl K, Meisel E, VanAgt E, Ottenhoff F, Hess M, Hauer B, Zahn R, et al. Is the atrial high rate episode diagnostic feature reliable in detecting paroxysmal episodes of atrial tachyarrhythmias? Pacing Clin Electrophysiol 1998; 21: 694-700.
18. Auricchio A, Hartung W, Geller C, Klein H,. Clinical relevance of stored electrograms for implantable cardioverter-defibrillator (ICD) troubleshooting and understanding of mechanisms for ventricular tachyarrhythmias. Am J Cardiol 1996; 78: 33-41.
19. Pollak WM, Simmons JD, Interian A Jr., Atapattu SA, Castellanos A, Myerburg RJ, Mitrani RD,. Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. Pacing Clin Electrophysiol 2001; 24: 424-429.
20. Gillis AM, Morck M,. Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol 2002; 13: 542-547.
21. Defaye P, Dournaux F, Mouton E,. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: The AIDA study. Pacing Clin Electrophysiol 1998; 21: 250-255.
22. Israel CW, Grönefeld G, Ehrlich JR, Li YG, Hohnloser SH,. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: Implications for optimal patient care. J Am Coll Cardiol 2004; 43: 47-52.
23. Cheung JW, Keating RJ, Stein KM, Markowitz SM, Iwai S, Shah BK, Lerman BB, et al. Newly detected atrial fibrillation following dual chamber pacemaker implantation. J Cardiovasc Electrophysiol 2006; 17: 1323-1328.
24. Orlov MV, Ghali JK, Araghi-Niknam M, Sherfesee L, Sahr D, Hettrick DA,; for the Atrial High Rate Trial Investigators. Asymptomatic atrial fibrillation in pacemaker recipients: Incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin Electrophysiol 2007; 30: 404-411.
25. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG,. Role of prophylactic anticoagulation for direct cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19: 851-855.
26. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ,. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation of less than 48 hours' duration. Ann Intern Med 1997; 126: 615-620.
27. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ,. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: S429-S456.
28. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, et al, MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: Report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003; 107: 1614-1619.
29. Capucci A, Santini M, Padeletti L, Gulizia M, Botto GL, Boriani G, Ricci R, et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005; 46: 1913-1192.
30. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk the TRENDS study. Circ Arrhythmia Electrophysiol 2009; 2: 474-480.
31. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, et al. ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366: 120-129.
32. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
33. Cabrera S, Mercé J, de Castro R, Aguirre C, Carmona A, Pinedo M, Salmerõn M, et al. Pacemaker clinic: An opportunity to detect silent atrial fibrillation and improve antithrombotic treatment. Europace 2011; 13: 1574-1579.
34. Fauchier L, Briand F, Soto F, Quennelle F, Levy J, Darmon J, Lellouche D, et al. Management of atrial tachyarrhythmias: Benefit of pacemaker diagnostics. Pacing Clin Electrophysiol 2003; 26: 233-238.
35. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC Jr, Cigarroa JE, Conti JB, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014 (in press; [Epub ahead of print])
36. Ip J, Waldo AL, Lip GY, Rothwell PM, Martin DT, Bersohn MM, Choucair WK, et al. IMPACT Investigators. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. Am Heart J 2009; 158: 364-370.
37. A Comparison of Apixaban Versus Aspirin for Preventing Stroke in Patients With Pacemakers (ARTESiA) ClinicalTrials.gov Identifier: NCT01938248. Available at http://clinicaltrials.gov/ct2/show/NCT01938248?term=Artesia&rank=1. Accessed March 1, 2014.
38. Decicco AE, Finkel JB, Greenspon AJ, Frisch DR,. Clinical significance of atrial fibrillation detected by cardiac implantable electronic devices. Heart Rhythm 2014; 11: 719-724.